10-year single-center experience of combined intravesical chemohyperthermia for nonmuscle invasive bladder cancer.

Aim: Owing to the limited efficacy and significant toxicity of most topical intravesical agents for the management of nonmuscle invasive bladder cancer (NMIBC), a search for new therapeutic modalities continues. This study evaluates the safety and efficacy of a relatively new modality, combined intravesical chemotherapy and hyperthermia, using the intravesical chemohyperthermia system.

Methods: The data summarize our 10 years of experience in the Department of Urology at Bnai Zion Medical Center, Israel.